Skip to main content

Tourette Disorder

1
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Emalex Biosciences
Emalex BiosciencesIL - Chicago
1 program
1
Ecopipam HydrochloridePhase 31 trial
Active Trials
NCT05615220Completed216Est. Feb 2025
Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
1 program
D-cycloserineN/A1 trial
Active Trials
NCT02582515Completed20Est. Aug 2017

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Emalex BiosciencesEcopipam Hydrochloride
Angeles TherapeuticsD-cycloserine

Clinical Trials (2)

Total enrollment: 236 patients across 2 trials

NCT05615220Emalex BiosciencesEcopipam Hydrochloride

Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Start: Jan 2023Est. completion: Feb 2025216 patients
Phase 3Completed

Augmentation of Brief Habit Reversal Training With D-cycloserine or Placebo

Start: Oct 2015Est. completion: Aug 201720 patients
N/ACompleted

Related Jobs

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.